About BioCryst
BioCryst is a company based in Durham (United States) founded in 1986.. The company has 580 employees as of December 31, 2024. BioCryst has completed 1 acquisition, including Astria Therapeutics. BioCryst offers products and services including Oral Small-Molecule Therapeutics and Protein Therapeutics. BioCryst operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Durham, United States
- Employees 580 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biocryst Pharmaceuticals, Inc.
-
Annual Revenue
$450.71 M36as on Dec 31, 2024
-
Net Profit
$-88.88 M60.77as on Dec 31, 2024
-
EBITDA
$-1.3 M98.73as on Dec 31, 2024
-
Latest Funding Round
$350 M (USD), Post-IPO
Nov 22, 2021
-
Investors
Kleiner Perkins
& 8 more
-
Employee Count
580
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioCryst
BioCryst is a publicly listed company on the NASDAQ with ticker symbol BCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BioCryst
BioCryst offers a comprehensive portfolio of products and services, including Oral Small-Molecule Therapeutics and Protein Therapeutics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for rare diseases like hereditary angioedema.
Innovative proteins targeting rare disease conditions.
Unlock access to complete
Unlock access to complete
Leadership Team
62 people
Operations Team
21 people
Software Development Team
17 people
Product Management Team
16 people
Legal and Compliance
12 people
Sales and Marketing
10 people
Human Resources and Administration
8 people
Rare Team
7 people
Unlock access to complete
Funding Insights of BioCryst
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $350.0M
-
First Round
First Round
(06 Aug 2007)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Post-IPO - BioCryst | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - BioCryst | Valuation |
investors |
|
| Feb, 2019 | Amount | Debt – Conventional - BioCryst | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BioCryst
BioCryst has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed by the firm.
|
Founded Year | Domain | Location | |
|
Private debt funds are managed across multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BioCryst
BioCryst has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Astria Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - BioCryst
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biocryst Comparisons
Competitors of BioCryst
BioCryst operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biocryst
Frequently Asked Questions about BioCryst
When was BioCryst founded?
BioCryst was founded in 1986 and raised its 1st funding round 21 years after it was founded.
Where is BioCryst located?
BioCryst is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Who is the current CEO of BioCryst?
Jon Stonehouse is the current CEO of BioCryst.
How many employees does BioCryst have?
As of Dec 31, 2024, the latest employee count at BioCryst is 580.
What is the annual revenue of BioCryst?
Annual revenue of BioCryst is $450.71M as on Dec 31, 2024.
What does BioCryst do?
BioCryst was founded in 1986 and is based in Durham, United States, within the biotechnology sector. Small molecule therapeutics are developed for orphan and autoimmune conditions, alongside antiviral agents. Operations focus on pipeline candidates such as BCX7353, targeted at hereditary angioedema, and BCX4430 (Galidesivir), a broad-spectrum antiviral for hemorrhagic fevers including SARS-CoV-2. RAPIVAB is also offered for influenza treatment.
Who are the top competitors of BioCryst?
BioCryst's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does BioCryst offer?
BioCryst offers Oral Small-Molecule Therapeutics and Protein Therapeutics.
Is BioCryst publicly traded?
Yes, BioCryst is publicly traded on NASDAQ under the ticker symbol BCRX.
How many acquisitions has BioCryst made?
BioCryst has made 1 acquisition, including Astria Therapeutics.
Who are BioCryst's investors?
BioCryst has 9 investors. Key investors include Kleiner Perkins, Royalty Pharma, TPG, Orbimed, and MidCap Financial.
What is BioCryst's ticker symbol?
The ticker symbol of BioCryst is BCRX on NASDAQ.